Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 15/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2420936 | 1.00 | NPY5R (0.46) | NPY5RDEGS1ABL1GSK3BMAPK14 | |
| SCHEMBL2455769 | 1.00 | NPY5R (0.46) | NPY5RDEGS1ABL1GSK3BMAPK14 | |
| SCHEMBL2417560 | 0.88 | NPY5R (0.49) | NPY5RDEGS1ABL1USP30 | |
| SCHEMBL2417423 | 0.88 | NPY5R (0.49) | NPY5RDEGS1ABL1USP30 | |
| SCHEMBL2417021 | 0.88 | NPY5R (0.49) | NPY5RDEGS1ABL1USP30 | |
| SCHEMBL2315496 | 0.82 | NPY5R (0.49) | NPY5RDEGS1ABL1USP30MAP4K4 | |
| SCHEMBL2317422 | 0.82 | NPY5R (0.49) | NPY5RDEGS1ABL1USP30MAP4K4 | |
| SCHEMBL2319121 | 0.78 | NPY5R (0.48) | NPY5RDEGS1ABL1GSK3BMAPK14 | |
| SCHEMBL2315476 | 0.75 | NPY5R (0.42) | NPY5RDEGS1ABL1USP30 | |
| SCHEMBL2418511 | 0.73 | NPY5R (0.47) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | NPY5R 1/4885DEGS1 3961/4885ABL1 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.